Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced that the randomized controlled pivotal clinical trial of its self‑developed Class 1 new drug, ZG006 (Alveltamig) for injection, as monotherapy for patients with advanced small cell lung cancer (SCLC) who had relapsed or progressed after prior platinum‑based chemotherapy and at least one other systemic therapy (third‑line and beyond), met the prespecified primary endpoint. The company will submit a Pre‑BLA (Biologics License Application) communication request to the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) and accelerate the marketing process for ZG006 for injection.
Regulatory & Development Milestone
| Item | Detail |
|---|---|
| Agency | CDE of the NMPA (China) |
| Milestone | Pivotal randomized controlled trial met the prespecified primary endpoint |
| Product | ZG006 (Alveltamig) for injection – self‑developed Class 1 new drug |
| Setting | Monotherapy, advanced SCLC, relapsed/progressed after platinum‑based chemotherapy and ≥1 other systemic therapy (third‑line and beyond) |
| Next Steps | Pre‑BLA communication request to be submitted to the CDE; marketing process to be accelerated |
| Designations | Breakthrough Therapy Designation (CDE, NMPA); Orphan‑Drug Designation (US FDA) |
Drug Profile & Mechanism of Action
- Molecule: ZG006 (Alveltamig), a trispecific T‑cell engager (TCE) targeting two distinct DLL3 epitopes and CD3.
- Mechanism: Dual‑epitope DLL3 engagement coupled with CD3‑mediated T‑cell redirection is designed to drive potent, targeted tumor cell killing in DLL3‑expressing SCLC – a lineage‑defining antigen in small cell lung cancer.
- Innovation: A first‑in‑class molecular format globally, with the potential to become a best‑in‑class molecule within the DLL3‑targeted landscape.
- Regulatory Support: Previously granted Breakthrough Therapy Designation by the CDE of the NMPA and Orphan‑Drug Designation by the US FDA, reflecting unmet need in relapsed/refractory SCLC.
Clinical Evidence – Pivotal Randomized Controlled Trial
| Endpoint | Result (ZG006 Monotherapy) | Comparator | Relative Benefit |
|---|---|---|---|
| Primary Endpoint (Prespecified) | Met | Randomized control arm | Positive pivotal result |
| Population | Advanced SCLC, relapsed/progressed after platinum‑based chemotherapy + ≥1 prior systemic therapy (3L+) | – | Deeply pretreated, high unmet need |
| Safety Profile | Not disclosed | – | – |
The pivotal trial was a randomized controlled study evaluating ZG006 as monotherapy in the third‑line and beyond setting – among the most difficult‑to‑treat segments of SCLC, where median survival with existing options remains short. Specific primary endpoint definition, hazard ratios, and response rates were not disclosed in the announcement.
Global Licensing & Commercial Outlook
- AbbVie Partnership: In December 2025, Zelgen entered into an agreement with AbbVie for the global development and commercialization of ZG006.
- Territory Split: AbbVie holds exclusive development and commercialization rights outside Greater China (including mainland China, the Hong Kong SAR and the Macao SAR); Zelgen retains rights in Greater China.
- Deal Economics: Consideration includes a USD 100 million upfront payment, near‑term milestone payments based on clinical trial progress and license‑option‑related payments of up to USD 60 million, plus milestone payments of up to USD 1.075 billion – headline biobucks approaching USD 1.235 billion.
- China Filing Path: The Pre‑BLA communication request to the CDE, supported by Breakthrough Therapy Designation, positions ZG006 for an accelerated domestic review track.
- Market Opportunity: Relapsed/refractory SCLC is a high‑mortality indication with limited effective third‑line options; a positive pivotal readout in this setting carries significant commercial weight for both Zelgen (Greater China) and AbbVie (ex‑Greater China).
- Watchpoints: Pre‑BLA meeting outcomes, filing timing, global regulatory strategy under AbbVie, and NRDL reimbursement sequencing in China were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the regulatory advancement of ZG006 (Alveltamig), including the planned Pre‑BLA communication with the CDE, potential BLA submission and approval, milestone payments under the AbbVie agreement, and commercialization expectations in China and globally. Actual results may differ due to risks including regulatory review outcomes, confirmatory safety and efficacy data, competitive dynamics in DLL3‑targeted and T‑cell engager therapies, and the pace of market adoption and reimbursement.-Fineline Info & Tech
